Abstract
Mutations in the fms-like tyrosine kinase 3 (FLT3) gene (internal tandem duplication (ITD) and point mutation in the tyrosine kinase domain, FLT3/D835) as well as the nucleophosmin (NPM1) gene are the most common abnormalities in adult acute myeloid leukemia (AML). Their significance in pediatric AML is still unclear. In this study we evaluated the frequency of FLT3 and NPM1 mutations in childhood AML. We also examined clinical features and outcome of these patients. FLT3 and NPM1 mutations were analysed in 42 and 37 childhood AML patients, respectively, using polymerase chain reaction (PCR) and direct sequencing. FLT3 mutations were detected in 4/42 patients (9.5%). The frequencies of FLT3/ITD and FLT3/D835 were the same, 2/42 (4.7%). NMP1 mutations were found in 1/37 patients (2.7%). FLT3 gene mutations were correlated with induction failure. Here we report the results of the study of FLT3 and NPM1 gene mutations in childhood AML patients in Serbia. Low frequencies of these molecular markers point out that these abnormalities are rare in this cohort of patients. Comparative study of data on NPM1 mutations in childhood AML revealed that various NPM1 gene mutation types are associated with childhood AML. Our findings as well as previously reported data, contributes to a hypothesis of different biology and etiology of adult and childhood AML. More extensive studies of NPM1 and FLT3 mutations in childhood AML are needed to determine their biological and clinical importance.
Similar content being viewed by others
References
Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cell. Leukemia. 1996;10:588–9.
Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematological malignancies. Blood. 2001;97:2434–9.
Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, et al. The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.
Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, et al. FLT3 internal tandem mutations in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood. 2003;102:2387–94.
Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, et al. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia. 2003;17:883–6.
Colovic N, Tosic N, Aveic S, Djuric M, Milic N, et al. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia. Ann Hematol. 2007;86:741–7.
Kang HJ, Hong SH, Kim IH, Park BK, Han KS, et al. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. Leuk Res. 2005;29:617–23.
Cordell JL, Pulford KA, Bigerna B, Roncador G, Banham A, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood. 1999;93:632–42.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, et al. Cytolasmatic nucleophosmin in acute myelogenous leukemia with normal karyotype. N Engl J Med. 2005;352:254–66.
Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood. 2007;109:874–85.
Cazzaniga G, Dell`Oro MG, Mecucci C, Giarin E, Masetti R, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106:1419–22.
Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 1997;11:1447–52.
Falini B, Marteli MP, Bolli N, Bonasso R, Ghia E, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005.
Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733–9.
Arrigoni P, Berreta C, Silvestri D, Rossi V, Rizzari C, et al. FLT3 internal tandem duplication in childhood acute myeloid leukemia: association with hyperleukocytosis in acute promyelocytic leukemia. Br J Haematol. 2003;120:89–92.
Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. Leukemia. 1999;13:38–43.
Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favourable prognostic significance. Blood. 2008;111:1552–9.
Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007;110:979–85.
Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia. 2007;21:366–7.
Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol. 1999;33:525–9.
Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89–94.
Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, et al. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer. 2002;94:3292–8.
Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108:3654–61.
Xu F, Taki T, Yang HW, Hanada R, Hongo T, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukemia as well as acute myeloid leukemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukemia in children. Br J Haematol. 1999;105:155–62.
Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011–20.
Mullighan CG, Kennedy A, Zhou X, Radtke I, Philips LA, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterised by a gene expression profile with dysregulated HOX gen expression distinct from MLL-rearranged leukemias. Leukemia. 2007;21:2000–9.
Chou WC, Tantg JL, Lin LI, Yao M, Tsay W, et al. Nucleophosmin mutations in de novo acute myeloid leukemia the age-dependent incidences and stability during disease evolution. Cancer Res. 2006;66:3310–6.
Shimada A, Taki T, Kubota C, Tawa A, Horibe K, et al. No nucleophosmin mutations in pediatric acute myeloid leukemia with normal karyotype: a study of the Japanese Childhood AML Cooperative Study Group. Leukemia. 2007;21:1307.
Acknowledgment
This study is supported by grant 143 051 from the Ministry of Science of Serbia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krstovski, N., Tosic, N., Janic, D. et al. Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature. Med Oncol 27, 640–645 (2010). https://doi.org/10.1007/s12032-009-9261-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-009-9261-5